EDGAR·FLOW

20/20 Biolabs, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
20/20 BioLabs (Nasdaq: AIDX), a $6.1M-asset company, executed a two-year contract with Vermont for OneTest Premium cancer screening covering ~4,500 firefighters with revenue expected in Q4 2026. The company raised $6M in Series E preferred stock in H1 2026, boosting cash to $3.63M (vs. $1.03M at year-end 2025). Nine-month OneTest revenue grew 4.1% to $1.36M with gross margin expanding to 32.8%; Q3 revenue declined YoY to $0.38M due to testing timing. The company introduced a lab franchise model and plans 2027 licensing of its protein tumor marker technology.
Why this rating

Vermont contract + franchise/licensing strategy are meaningful distribution expansions relative to $1.36M 9-month revenue base. $6M Series E funding (66% of total assets) is material for cash runway. However, Q3 revenue decline and $5.06M 9-month net loss temper outlook.

Tradability signal
NO TRADE

No trade: price $0.19 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$0.19 ▼ 1.32%
at our read · unknown
$0.19
+10 min · unknown
$0.19 ▼ 1.58%
+30 min · unknown
$0.19 ▼ 1.05%
+1 hr · unknown
$0.19 ▼ 2.11%
+4 hrs · unknown
$0.18 ▼ 3.68%

The stock had already moved +1.33% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ AIDX · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.